Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma

LONDON, April 8, 2014 /PRNewswire/ --

The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:

http://www.investor-edge.com/914-register

Shares in Peregrine Pharmaceuticals Inc. edged 2.72% higher, finishing Monday's session at $1.89. The stock fluctuated between $1.88 and $2.09 during the session with a trading volume of 6.75 million shares as compared with its three months average volume of 5.10 million shares. Shares in Peregrine Pharmaceuticals Inc. have fallen by 21.25% in the last one month, while the stock has surged 19.62% in the previous three months and 35.97% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 1.06% during the trading session and charted up 3.19% in the previous three months. Furthermore, the company's stock has a Relative Strength Index (RSI) of 42.16 and is trading above its 200-day moving average of $1.55. Sign up today to read free research on PPHM at:

http://www.investor-edge.com/914-PPHM-08Apr2014.pdf

On Monday, shares in Agios Pharmaceuticals Inc. ended the session at $45.35, up 27.82%. A total of 2.69 million shares were traded as compared with its three months average volume of 0.36 million shares. During the session, the stock traded between $41.37 and $46.00. Agios Pharmaceuticals Inc.'s shares have rallied 23.97% in the past three trading sessions, 88.96% in the previous three months and 89.35% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 1.06% during the trading session and has declined 3.26% in the last one month. Further, the company's stock has an RSI of 44.90 and is trading above its 50-day moving average of $34.73. On Sunday, April 6, 2014, the company announced that data from its lead, first-in-class program AG-221 will be presented at a Clinical Trials Symposium. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation. Sign up today to read free research on AGIO at:

http://www.investor-edge.com/914-AGIO-08Apr2014.pdf

Idenix Pharmaceuticals Inc.'s stock finished Monday's session at $5.81, up 12.38%. A total of 4.19 million shares were traded which is above its three months average volume of 1.54 million shares. The stock vacillated between $5.12 and $5.96 during the session. Idenix Pharmaceuticals Inc.'s shares have lost 12.37% in the last one month and 2.84% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 1.06% during the trading session, and has fallen by 2.85% in the previous three trading sessions. Additionally, the company's stock has an RSI of 30.86 and is trading above its 200-day moving average of $5.26. On the same day, the company announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus (HCV) infection. Sign up today to read free research on IDIX at:

http://www.investor-edge.com/914-IDIX-08Apr2014.pdf

Shares in Lexicon Pharmaceuticals Inc. closed Monday's session at $1.64, up 3.14%, after hitting a new 52-week low of $1.54. The stock oscillated between $1.54 and $1.68 during the trading session with a trading volume of 2.00 million shares, which is above its three months average volume of 1.21 million shares. Shares in Lexicon Pharmaceuticals Inc. have declined 8.38% in the last one month and 8.84% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 1.06% during the trading session, while the same has charted up 3.19% in the last three months. Moreover, the company's stock has an RSI of 37.38 and is trading below its 50-day and 200-day moving averages of $1.79 and $2.16, respectively. Sign up today to read free research on LXRX at:

http://www.investor-edge.com/914-LXRX-08Apr2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge